Burleson & Co’s Quince Therapeutics QNCX Stock Holding History

Burleson & Co’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$5.36K	Sell	42 -1,478	-97%	-$247K	﹤0.01%	302
2022 Q3	$404K	Buy	1,520 +219	+17%	+$83.4K	0.09%	102
2022 Q2	$578K	Buy	1,301 +178	+16%	+$126K	0.13%	89
2022 Q1	$1.39M	Buy	1,123 +42	+4%	+$57.2K	0.22%	75
2021 Q4	$2.73M	Buy	1,081 +405	+60%	+$2.47M	0.4%	47
2021 Q3	$12.4M	Buy	676 +20	+3%	+$318K	1.84%	16
2021 Q2	$6.95M	Buy	656 +55	+9%	+$461K	1.01%	26
2021 Q1	$4.33M	Buy	601 +394	+190%	+$2.84M	0.7%	26
2020 Q4	$1.15M	Sell	207 -260	-56%	-$2.3M	0.2%	75
2020 Q3	$4.48M	Buy	467 +196	+72%	+$1.78M	0.85%	25
2020 Q2	$2.39M	Buy	271 +110	+68%	+$1.01M	0.52%	44
2020 Q1	$1.48M	Buy	161 +120	+293%	+$1.18M	0.39%	57
2019 Q4	$470K	Buy	+41	New	+$247K	0.13%	97

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Burleson & Co's QNCX Position: Q4 2022 in Review

Burleson & Co reduced its Quince Therapeutics (QNCX) stake by 97% in Q4 2022, selling an estimated $247K and leaving 42 shares worth $5.36K. The position accounts for ﹤0.01% of the portfolio, ranked #302.

Burleson & Co first reported a position in QNCX in Q4 2019 and has held it in 13 quarters since. The position peaked at $12.4M in Q3 2021. 48 funds tracked by Wall St. Rank hold QNCX as of Q4 2022.

Burleson & Co held 42 shares of Quince Therapeutics worth $5.36K as of Q4 2022.
Burleson & Co sold 1,478 Quince Therapeutics shares in Q4 2022, an estimated $247K.
Quince Therapeutics made up ﹤0.01% of Burleson & Co's portfolio in Q4 2022, its #302 holding.
Burleson & Co first reported a position in Quince Therapeutics in Q4 2019 and has held it in 13 quarters since.
Burleson & Co's Quince Therapeutics position peaked at $12.4M in Q3 2021.
48 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2022.

Based on Burleson & Co's 13F filing for Q4 2022, filed 31 Jan 2023.